137 related articles for article (PubMed ID: 14510946)
1. The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups.
Oosterveld M; Wittebol SH; Lemmens WA; Kiemeney BA; Catik A; Muus P; Schattenberg AV; de Witte TJ
Br J Haematol; 2003 Oct; 123(1):81-9. PubMed ID: 14510946
[TBL] [Abstract][Full Text] [Related]
2. Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy.
Gauthier J; Damaj G; Langlois C; Robin M; Michallet M; Chevallier P; Beguin Y; N'guyen S; Bories P; Blaise D; Cornillon J; Clavert A; Mohty M; Huynh A; Thiébaut-Bertrand A; Vigouroux S; Duhamel A; Yakoub-Agha I
Transplantation; 2015 Aug; 99(8):1672-80. PubMed ID: 25769079
[TBL] [Abstract][Full Text] [Related]
3. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
[TBL] [Abstract][Full Text] [Related]
4. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
5. Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation.
Koenecke C; Göhring G; de Wreede LC; van Biezen A; Scheid C; Volin L; Maertens J; Finke J; Schaap N; Robin M; Passweg J; Cornelissen J; Beelen D; Heuser M; de Witte T; Kröger N;
Haematologica; 2015 Mar; 100(3):400-8. PubMed ID: 25552702
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic stem cell transplantation in patients with myelodysplastic syndrome: outcome analysis according to the International Prognostic Scoring System.
Rubio S; Martins C; Lacerda JF; Carmo JA; Lourenço F; Lacerda JM
Acta Med Port; 2006; 19(5):343-7. PubMed ID: 17376319
[TBL] [Abstract][Full Text] [Related]
7. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
8. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
[TBL] [Abstract][Full Text] [Related]
9. Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes.
Lee YJ; Park SW; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Lee WS; Lee SM; Joo YD; Kim H; Lee HS; Kim YS; Cho YY; Moon JH; Sohn SK
Ann Hematol; 2016 Oct; 95(11):1795-804. PubMed ID: 27530461
[TBL] [Abstract][Full Text] [Related]
10. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study.
Woods WG; Kobrinsky N; Buckley J; Neudorf S; Sanders J; Miller L; Barnard D; Benjamin D; DeSwarte J; Kalousek D
J Clin Oncol; 1993 Aug; 11(8):1448-57. PubMed ID: 8336184
[TBL] [Abstract][Full Text] [Related]
11. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.
Damaj G; Duhamel A; Robin M; Beguin Y; Michallet M; Mohty M; Vigouroux S; Bories P; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Legrand F; Deconinck E; Fegueux N; Clement L; Dauriac C; Maillard N; Cornillon J; Ades L; Guillerm G; Schmidt-Tanguy A; Marjanovic Z; Park S; Rubio MT; Marolleau JP; Garnier F; Fenaux I; Yakoub-Agha I
J Clin Oncol; 2012 Dec; 30(36):4533-40. PubMed ID: 23109707
[TBL] [Abstract][Full Text] [Related]
12. Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party.
Scheid C; de Wreede L; van Biezen A; Koenecke C; Göhring G; Volin L; Maertens J; Finke J; Passweg J; Beelen D; Cornelissen JJ; Itälä-Remes M; Chevallier P; Russell N; Petersen E; Milpied N; Richard Espiga C; Peniket A; Sierra J; Mufti G; Crawley C; Veelken JH; Ljungman P; Cahn JY; Alessandrino EP; de Witte T; Robin M; Kröger N
Bone Marrow Transplant; 2017 Nov; 52(11):1519-1525. PubMed ID: 28892084
[TBL] [Abstract][Full Text] [Related]
13. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
[TBL] [Abstract][Full Text] [Related]
14. Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
Ferrero D; Crisà E; Marmont F; Audisio E; Frairia C; Giai V; Gatti T; Festuccia M; Bruno B; Riera L; Passera R; Boccadoro M
Ann Hematol; 2014 Aug; 93(8):1391-400. PubMed ID: 24705888
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System.
Jung KS; Kim YJ; Kim YK; Park SK; Kim HG; Kim SJ; Park J; Choi CW; Do YR; Kim I; Park S; Mun YC; Jeong SH; Kim MK; Yi HG; Chang MH; Kim SY; Lee JH; Jang JH
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):656-664. PubMed ID: 31375393
[TBL] [Abstract][Full Text] [Related]
16. Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study.
Lee JH; Kim YJ; Sohn SK; Yoon SS; Kim H; Cheong JW; Lee WS; Lee GW; Lim SN; Kim MK; Lee HS; Kim HJ;
Leuk Res; 2017 Sep; 60():135-144. PubMed ID: 28826063
[TBL] [Abstract][Full Text] [Related]
17. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis.
Koreth J; Pidala J; Perez WS; Deeg HJ; Garcia-Manero G; Malcovati L; Cazzola M; Park S; Itzykson R; Ades L; Fenaux P; Jadersten M; Hellstrom-Lindberg E; Gale RP; Beach CL; Lee SJ; Horowitz MM; Greenberg PL; Tallman MS; DiPersio JF; Bunjes D; Weisdorf DJ; Cutler C
J Clin Oncol; 2013 Jul; 31(21):2662-70. PubMed ID: 23797000
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R.
Della Porta MG; Alessandrino EP; Bacigalupo A; van Lint MT; Malcovati L; Pascutto C; Falda M; Bernardi M; Onida F; Guidi S; Iori AP; Cerretti R; Marenco P; Pioltelli P; Angelucci E; Oneto R; Ripamonti F; Bernasconi P; Bosi A; Cazzola M; Rambaldi A;
Blood; 2014 Apr; 123(15):2333-42. PubMed ID: 24558201
[TBL] [Abstract][Full Text] [Related]
19. Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome.
Komrokji RS; Corrales-Yepez M; Al Ali N; Kharfan-Dabaja M; Padron E; Fields T; Lancet JE; List AF
Cancer; 2012 May; 118(10):2659-64. PubMed ID: 21956402
[TBL] [Abstract][Full Text] [Related]
20. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.
Mishra A; Corrales-Yepez M; Ali NA; Kharfan-Dabaja M; Padron E; Zhang L; Epling-Burnette PK; Pinilla-Ibarz J; Lancet JE; List AF; Komrokji RS
Am J Hematol; 2013 Jul; 88(7):566-70. PubMed ID: 23605934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
